A detailed history of Eco R1 Capital, LLC transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Eco R1 Capital, LLC holds 4,288,120 shares of CRNX stock, worth $240 Million. This represents 9.5% of its overall portfolio holdings.

Number of Shares
4,288,120
Previous 4,155,375 3.19%
Holding current value
$240 Million
Previous $186 Million 17.69%
% of portfolio
9.5%
Previous 6.58%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$43.83 - $54.98 $5.82 Million - $7.3 Million
132,745 Added 3.19%
4,288,120 $219 Million
Q1 2024

May 15, 2024

BUY
$34.76 - $46.81 $74.5 Million - $100 Million
2,142,858 Added 106.48%
4,155,375 $195 Million
Q4 2023

Feb 14, 2024

BUY
$25.62 - $37.07 $12.4 Million - $17.9 Million
482,254 Added 31.51%
2,012,517 $71.6 Million
Q3 2023

Nov 14, 2023

BUY
$15.97 - $30.59 $3.19 Million - $6.12 Million
200,000 Added 15.03%
1,530,263 $45.5 Million
Q2 2022

Aug 15, 2022

BUY
$16.49 - $27.64 $8.91 Million - $14.9 Million
540,054 Added 68.34%
1,330,263 $24.8 Million
Q1 2022

May 16, 2022

BUY
$17.15 - $28.31 $3.43 Million - $5.66 Million
200,040 Added 33.9%
790,209 $17.3 Million
Q4 2021

Feb 14, 2022

BUY
$19.35 - $28.41 $11.4 Million - $16.8 Million
590,169 New
590,169 $16.8 Million
Q3 2020

Nov 16, 2020

SELL
$13.62 - $17.66 $11.7 Million - $15.2 Million
-859,802 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$13.04 - $23.23 $6.65 Million - $11.8 Million
509,802 Added 145.66%
859,802 $15.1 Million
Q1 2020

May 15, 2020

BUY
$11.52 - $26.46 $4.03 Million - $9.26 Million
350,000 New
350,000 $5.15 Million

Others Institutions Holding CRNX

About Crinetics Pharmaceuticals, Inc.


  • Ticker CRNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,752,800
  • Market Cap $3.01B
  • Description
  • Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...
More about CRNX
Track This Portfolio

Track Eco R1 Capital, LLC Portfolio

Follow Eco R1 Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Eco R1 Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Eco R1 Capital, LLC with notifications on news.